Live
FierceBiotechLilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trialEndpoints NewsCongruence starts human trials for first drug, raises $40MEndpoints NewsLantern raises $30M from Morgan Health, Echo Health VenturesThermo FisherMirova Trims Position in Thermo Fisher Scientific Inc. $TMO - MarketBeatEndpoints NewsUpdated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggestThermo FisherGroupama Asset Management Boosts Thermo Fisher Scientific Holdings - National TodayIlluminaJPMorgan Chase Boosts Illumina Stake by 17.5% - National TodayIlluminaJPMorgan Chase & Co. Acquires 124,246 Shares of Illumina, Inc. $ILMN - MarketBeat10x Genomics Blog10x Genomics CRISPR Brain Atlas Collaboration And What It Means For Investors - Yahoo Finance SingaporeWatersIs Waters Corporation Stock Underperforming the Dow? - BarchartWatersIs Waters Corporation Stock Underperforming the Dow? - FinancialContentWatersIs Waters Corporation Stock Underperforming the Dow? - Yahoo Finance
Roche Media Jan 27, 2026

Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist | PharmExec - Pharmaceutical Executive

Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist | PharmExec - Pharmaceutical Executive

Original
Body unavailable. Use the original source.

Directory

59 All